

●► **Latigo Biotherapeutics**

*(FDA, FTD)*

The FDA grants Fast Track Designation to Latigo Biotherapeutics' LTG-001, a Nav1.8 inhibitor for acute pain

---

●► **Celltrion**

*(FDA, Approval)*

FDA approves Celltrion's STOBOCLO, a biosimilar to PROLIA and OSENVELT, a biosimilar to XGEVA; expected to be available in the U.S. in June 2025

---

●► **BioArctic AB**

*(Approval, TGA)*

Therapeutic Goods Administration refuses approval for lecanemab in treating mild Alzheimer's symptoms

---

●► **Sun Pharma**

*(Acquisition)*

Sun Pharma expands Oncology portfolio with Checkpoint Therapeutics acquisition

---

●► **AMGEN AND KYOWA KIRIN**

*(Clinical trials result)*

Amgen and Kyowa Kirin announce key Phase 3 results for rocatinlimab in moderate-to-severe atopic dermatitis





●▶ **Biocon**

*(Clinical trials result)*

Biocon Biologics reports positive Phase 3 results for YESINTEK™, ustekinumab biosimilar for chronic plaque psoriasis

---

●▶ **HanAll Biopharma**

*(ODD, MHLW)*

HanAll Biopharma's batoclimab receives Orphan Drug Designation in Japan, advancing treatment for active thyroid eye disease (TED)

---

●▶ **Genentech**

*(FDA, Approval)*

Genentech's TNKase® gains FDA approval for use in acute ischemic stroke

---

●▶ **Genentech**

*(sBLA FDA)*

Genentech's Gazyva advances in regulatory process as FDA accepts sBLA for lupus nephritis

